SLNO Stock Down -22% after 6-Day Loss Streak
Soleno Therapeutics (SLNO) stock hit day 6 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -22% return. The company has lost about $745 Mil in value over the last 6 days, with its current market capitalization at about $3.4 Bil. The stock remains 48.6% above its value at the end of 2024. This compares with year-to-date returns of 9% for the S&P 500.
SLNO is a clinical-stage biopharmaceutical company offering Diazoxide Choline Controlled-Release, a once-daily oral tablet for treating Prader-Willi Syndrome. Is this drop a warning sign or a setup for rebound? Deep dive with Buy or Sell SLNO.
Comparing SLNO Stock Returns With The S&P 500
The following table summarizes the return for SLNO stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | SLNO | S&P 500 |
|---|---|---|
| 1D | -1.9% | -0.6% |
| 6D (Current Streak) | -22.1% | 0.6% |
| 1M (21D) | -23.2% | 1.7% |
| 3M (63D) | -11.6% | 7.5% |
| YTD 2025 | 48.6% | 9.0% |
| 2024 | 11.7% | 23.3% |
| 2023 | 1932.8% | 24.2% |
| 2022 | 382.9% | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact. Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: SLNO Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 44 S&P constituents with 3 days or more of consecutive gains and 32 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 28 | 8 |
| 4D | 4 | 20 |
| 5D | 3 | 3 |
| 6D | 7 | 1 |
| 7D or more | 2 | 0 |
| Total >=3 D | 44 | 32 |
Key Financials for Soleno Therapeutics (SLNO)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-38.7 Mil | $-184.4 Mil |
| Net Income | $-39.0 Mil | $-175.8 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $0 | $32.7 Mil |
| Operating Income | $-42.8 Mil | $-5.4 Mil |
| Net Income | $-43.8 Mil | $-4.7 Mil |
The losing streak SLNO stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.